Ipca Laboratories Limited, headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture and export of active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1949, the company has achieved significant milestones, including a robust presence in over 100 countries and a diverse product portfolio that encompasses a wide range of therapeutic areas such as cardiovascular, anti-infective, and pain management. With a commitment to quality and innovation, Ipca Laboratories stands out for its extensive range of generic formulations and APIs, which are produced in state-of-the-art facilities adhering to international standards. The company has garnered a strong market position, recognised for its consistent growth and contributions to healthcare, making it a trusted name in the global pharmaceutical landscape.
How does Ipca Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ipca Laboratories's score of 37 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2025, Ipca Laboratories reported total carbon emissions of approximately 582,391,000 kg CO2e, comprising 169,992,000 kg CO2e from Scope 1, 124,512,000 kg CO2e from Scope 2, and 287,887,000 kg CO2e from Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, with disclosures across all three scopes. For the previous year, 2024, the company recorded emissions of about 614,543,000 kg CO2e, with Scope 1 emissions at 174,538,000 kg CO2e, Scope 2 at 137,345,000 kg CO2e, and Scope 3 at 306,660,000 kg CO2e. In 2023, emissions were approximately 304,994,000 kg CO2e, with Scope 1 at 124,880,000 kg CO2e and Scope 2 at 179,114,000 kg CO2e. Ipca Laboratories has set ambitious targets to reduce its carbon footprint, aiming for a 20% reduction in Scope 1 and Scope 2 emissions by 2030, with the baseline year being 2022. This commitment aligns with their broader climate strategy, which includes a near-term target for Scope 1 emissions reduction. The company is also committed to achieving net-zero emissions, as indicated by their status with the Science Based Targets initiative (SBTi). This commitment underscores their dedication to sustainable practices within the pharmaceutical sector, reflecting a proactive stance on climate change and environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 51,938,620 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 598,518,280 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 6,451,465,560 | - | - | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ipca Laboratories has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Ipca Laboratories's sustainability data and climate commitments